5 305

Cited 29 times in

Characteristics and prognosis of chromophobe non-metastatic renal cell carcinoma: a multicenter study

Authors
 Won Ki Lee  ;  Seok-Soo Byun  ;  Hyeon Hoe Kim  ;  Koon Ho Rha  ;  Tae-Kon Hwang  ;  Gyung Tak Sung  ;  Wan Lee  ;  Jae Sung Lim  ;  Young Beom Jeong  ;  Tae Gyun Kwon 
Citation
 INTERNATIONAL JOURNAL OF UROLOGY, Vol.17(11) : 898-904, 2010 
Journal Title
 INTERNATIONAL JOURNAL OF UROLOGY 
ISSN
 0919-8172 
Issue Date
2010
MeSH
Adolescent ; Adult ; Age Factors ; Aged ; Analysis of Variance ; Biopsy, Needle ; Carcinoma, Renal Cell/mortality* ; Carcinoma, Renal Cell/pathology* ; Carcinoma, Renal Cell/secondary ; Carcinoma, Renal Cell/therapy ; Cohort Studies ; Combined Modality Therapy ; Confidence Intervals ; Disease-Free Survival ; Female ; Humans ; Immunohistochemistry ; Kaplan-Meier Estimate ; Kidney Neoplasms/mortality* ; Kidney Neoplasms/pathology* ; Kidney Neoplasms/therapy ; Male ; Middle Aged ; Multivariate Analysis ; Neoplasm Invasiveness/pathology ; Neoplasm Staging ; Nephrectomy/methods ; Prognosis ; Proportional Hazards Models ; Retrospective Studies ; Risk Assessment ; Sex Factors ; Survival Analysis ; Young Adult
Keywords
chromophobe ; conventional ; pathology ; renal cell carcinoma ; survival
Abstract
OBJECTIVES: To analyze the characteristics and the prognostic significance of chromophobe renal cell carcinomas (chRCC). METHODS: Data about 2981 patients with non-metastatic renal cell carcinomas (RCC) at the time of surgery were retrospectively collected from 26 institutions between 1998 and 2008. All patients had undergone partial or radical nephrectomies. Of the 2981 patients, 2602 patients with conventional RCC (cRCC) and 148 with chRCC were studied. Clinical and pathological parameters were determined in all patients. Recurrence-free survival (RFS) and cancer-specific survival (CSS) were assessed. RESULTS: Patients with chRCC differed significantly from those with cRCC on the following parameters: younger age (P=0.026), greater female ratio (P<0.001), and larger tumor diameter (P<0.001). Both groups were alike with respect to body mass index (P=0.943), Eastern Cooperative Oncology Group performance status (P=0.163), T stage (P=0.375), and Fuhrman's grade (P=0.134). The 5-year RFS rates in patients with chRCC and cRCC were 82.7% and 83.3%, respectively (P=0.762). The 5-year CSS rates in patients with chRCC and cRCC were 88.8% and 92.2%, respectively (P=0.980). Both groups showed equivalent oncological outcomes in terms of RFS and CSS for cases stratified by T stage and Fuhrman's grade. In multivariate analysis, the histological subtype was not retained as an independent prognostic variable (RFS: P=0.893; CSS: P=0.729). CONCLUSIONS: Despite being significantly different from cRCC in terms of several clinical and pathological parameters, chRCC shows equivalent oncological outcomes.
Full Text
http://onlinelibrary.wiley.com/doi/10.1111/j.1442-2042.2010.02630.x/abstract
DOI
10.1111/j.1442-2042.2010.02630.x
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Urology (비뇨의학교실) > 1. Journal Papers
Yonsei Authors
Rha, Koon Ho(나군호) ORCID logo https://orcid.org/0000-0001-8588-7584
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/102286
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links